

**Additional File 5.** Comparison of senescence-associated secretory phenotype (SASP) proteins between subjects who spontaneously cleared HCV (SC group) versus controls (C group).

Marker	Un-adjusted			Adjusted		
	AMR (95%CI)	p-value	q-value	aAMR (95%CI)	p-value	q-value
EGF	1.26 (1.03–1.54)	<b>0.026</b>	<b>0.084</b>	1.29 (1.05–1.58)	<b>0.019</b>	<b>0.063</b>
Eotaxin	1.47 (1.03–2.10)	<b>0.037</b>	<b>0.100</b>	1.58 (1.07–2.32)	<b>0.025</b>	<b>0.063</b>
GRO-alpha/KC	1.10 (0.96–1.27)	0.187	0.243	1.12 (0.97–1.30)	0.139	0.201
GM-CSF	1.19 (0.97–1.46)	0.103	0.168	1.19 (0.97–1.48)	0.105	0.160
IFN-gamma	1.13 (0.97–1.31)	0.113	0.173	1.11 (0.95–1.30)	0.176	0.235
IL-1beta	1.22 (1.01–1.46)	<b>0.042</b>	<b>0.100</b>	1.21 (1.00–1.45)	0.051	0.095
IL-1alpha	1.18 (0.99–1.41)	0.065	0.121	1.22 (1.01–1.46)	<b>0.038</b>	<b>0.081</b>
IL-1RA	1.33 (1.12–1.57)	<b>0.002</b>	<b>0.024</b>	1.29 (1.08–1.53)	<b>0.006</b>	<b>0.060</b>
IL-2	1.19 (0.93–1.53)	0.182	0.243	1.19 (0.92–1.54)	0.185	0.235
IL-6	1.08 (0.89–1.33)	0.438	0.495	1.09 (0.89–1.34)	0.406	0.459
IL-7	1.15 (0.97–1.38)	0.120	0.174	1.17 (0.98–1.41)	0.096	0.155
IL-8	1.16 (1.00–1.33)	<b>0.050</b>	0.108	1.17 (1.01–1.36)	<b>0.041</b>	<b>0.081</b>
IL-13	1.24 (1.04–1.48)	<b>0.022</b>	<b>0.081</b>	1.24 (1.03–1.49)	<b>0.025</b>	<b>0.063</b>
IL-15	1.03 (0.87–1.23)	0.736	0.797	1.00 (0.83–1.20)	0.986	0.986
IL-18	1.46 (1.12–1.91)	<b>0.008</b>	0.0476	1.45 (1.09–1.91)	<b>0.013</b>	<b>0.060</b>
IP-10	1.60 (1.12–2.29)	<b>0.013</b>	<b>0.055</b>	1.50 (1.06–2.13)	<b>0.027</b>	<b>0.063</b>
MCP-1	1.23 (0.87–1.74)	0.245	0.303	1.30 (0.88–1.92)	0.189	0.235
RANTES	1.02 (0.81–1.28)	0.868	0.902	0.92 (0.73–1.17)	0.495	0.536
SDF-1alpha	1.27 (1.07–1.50)	<b>0.007</b>	<b>0.048</b>	1.24 (1.04–1.46)	<b>0.016</b>	<b>0.060</b>
FGF-2	1.13 (0.98–1.31)	0.103	0.168	1.15 (0.98–1.34)	0.085	0.147
HGF	1.28 (1.07–1.52)	<b>0.009</b>	<b>0.048</b>	1.29 (1.07–1.54)	<b>0.009</b>	<b>0.060</b>
Beta-NGF	1.11 (1.00–1.24)	0.054	0.108	1.14 (1.03–1.27)	<b>0.016</b>	<b>0.060</b>
PLGF-1	1.28 (1.02–1.62)	<b>0.038</b>	<b>0.100</b>	1.40 (1.10–1.80)	<b>0.010</b>	<b>0.060</b>
SCF	1.33 (1.13–1.57)	<b>0.001</b>	<b>0.024</b>	1.31 (1.11–1.55)	<b>0.002</b>	<b>0.060</b>
TNF-alpha	1.10 (0.94–1.29)	0.257	0.303	1.10 (0.93–1.30)	0.285	0.337
TNF-beta	0.99 (0.80–1.22)	0.920	0.920	1.04 (0.84–1.28)	0.746	0.776

**Statistics:** Data were calculated by Generalized Linear Models (GLM) with a gamma distribution (log-link). Multivariable models were adjusted by age, sex, IL28 genotype, and AST, previously selected by a stepwise method (forward) (see **Results Section**). The q-values represent p-values corrected for multiple testing using the False Discovery Rate (FDR). Significant differences are shown in bold.

**Abbreviations:** AMR, arithmetic mean ratio; aAMR, adjusted AMR; 95%CI, 95% of confidence interval; p, level of significance; q, corrected level of significance; EGF, epidermal growth factor; GRO-alpha/KC, chemokine growth-regulated protein alpha; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; MCP-1, C-C motif chemokine ligand 2; RANTES, C-C motif chemokine ligand 5; SDF-1alpha, stromal cell-derived factor 1alpha; FGF-2, fibroblast growth factor 2; HGF, hepatocyte growth factor; Beta-NGF, nerve growth factor  $\beta$ ; PLGF-1, placental growth factor; SCF, skp, cullin, F-box containing complex; TNF, tumoral necrosis factor.